uMCP-1 Levels Research Articles

Levels of Inflammatory Cytokines in Type 2 Diabetes Patients with Different Urinary Albumin Excretion Rates and Their Correlation with Clinical Variables

Although the pathogenetic mechanism of DN has not been elucidated, an inflammatory mechanism has been suggested as a potential contributor. This study was designed to explore the relationship between low-grade inflammation and renal microangiopathy in T2DM. A total of 261 diabetic subjects were divided into three groups according to UAE: a normal albuminuria group, a microalbuminuria group, and a macroalbuminuria group. A control group was also chosen. Levels of hs-CRP, TNF-α, uMCP-1, SAA, SCr, BUN, serum lipid, blood pressure, and HbA1c were measured in all subjects. Compared with the normal controls, levels of hs-CRP, TNF-α, uMCP-1, and SAA in T2DM patients were significantly higher. They were also elevated in the normal albuminuria group, P < 0.05. Compared with the normal albuminuria group, levels of these inflammatory cytokines were significantly higher in the microalbuminuria and macroalbuminuria group, P < 0.01. The macroalbuminuria group also showed higher levels than the microalbuminuria group, P < 0.01. Also they were positively correlated with UAE, SBP, DBP, LDL-C, and TC. We noted no significance correlated with course, TG, or HDL-C. Only TNF-α; was positively correlated with HbA1c. This study revealed the importance of these inflammatory cytokines in DN pathogenesis. Further studies are needed to fully establish the potential of these cytokines as additional biomarkers for the development of DN.

Clinical significance of urinary Monocyte Chemoattractant Protein-1 (uMCP-1) in Indian type 2 diabetic patients at different stages of diabetic nephropathy

ObjectiveMonocyte Chemoattractant Protein-1 (MCP-1) is the strongest known chemotactic factor for monocytes and is upregulated in diabetic nephropathy. So measuring urinary MCP-1 is of great significance in the diagnosis and intervention of early diabetic nephropathy. This study aims at determining the levels of urinary MCP-1 (uMCP-1) at different stages of diabetic nephropathy and to see its correlation with other parameters in Indian type2 diabetic subjects. Materials and methodsA total of 64 (M:F; 40:24) type 2 diabetic subjects were divided into three groups based on their renal function and were compared with non-diabetic controls (Group 1) n=20 (M:F; 13:7). The study groups were Group 2 (normoalbuminuria) n=16, Group 3 (microalbuminuria) n=23 and Group 4 (macroalbuminuria) n=25. Demographic, anthropometric and biochemical details were recorded for all the subjects. Urinary MCP-1 levels were measured by using solid phase ELISA method. ResultsMean levels of uMCP-1 in subjects with type 2 diabetes were significantly higher than in controls (p<0.05). The levels of uMCP-1 in type 2 diabetic subjects increased gradually with deteriorating renal function (p=0.006). There was a significant difference in urinary MCP-1 levels between Group 2 and Group 1 (p<0.001). Levels of uMCP-1 were significantly higher in subjects with eGFR <60ml/min compared to eGFR >60ml/min (p=0.008). uMCP-1 levels correlated positively with uACR or uPCR (r=0.551, p<0.0001), urea (r=0.43, p<0.0001) and creatinine (r=0.478, p<0.0001). A negative correlation between uMCP-1 and eGFR (r=−0.338, p=0.006) was noted. ConclusionOur study demonstrated that urinary MCP-1 levels increased gradually in type 2 diabetic subjects with deteriorating renal function. It is significantly associated with the other risk factors of diabetic nephropathy.

Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in Type 2 diabetes mellitus

Objective Monocyte chemoattractant protein -1(MCP-1) is a cytokine that exhibits most potent chemotactic activity toward monocytes. It is suggested to be implicated in the development and progression of diabetic nephropathy by playing a role in infiltration of monocyte/macrophage. Recent studies have demonstrated that urinary monocyte chemoattractant protein-1 (uMCP-1) is different at different stages of diabetic nephropathy. Based on these findings, the aim of this study is to examine the level of uMCP-1 and its clinical significance at different stages of diabetic nephropathy and at the same time to describe the relationship between uMCP-1 and the various parameters. Methods Fifty-nine cases with type 2 diabetes mellitus (T2DM) were divided into three groups according to urine albumin excretion (UAE): normal albuminuria group, microalbuminuria group and macroalbuminuria group. The levels of uMCP-1, protein excretion, blood urea nitrogen (BUN), serum creatinine (s-Cr), glycohemoglobin A1c (HbA1c), blood pressure and blood fat were measured in 59 patients with T2DM and 27 healthy adults as controls. Results Compared with normal control, levels of uMCP-1 in T2DM were significantly high, which were already elevated in normal albuminuria group. Compared with normal albuminuria group, levels of uMCP-1 in microalbuminuria group and macroalbuminuria group were significantly high. Levels of uMCP-1 in macroalbuminuria group were higher than those in microalbuminuria group. The level of uMCP-1 was positively correlated with UAE, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) in T2DM patients, while it had no significant correlation with HbA1c , triglyceride (TG) and high density lipoprotein cholesterol (HDL-C). Conclusions: MCP-1 is suggested to be implicated in the development and progression of diabetic nephropathy. It is very important to measure the level of uMCP-1 in the diagnosis and intervention of early diabetic nephropathy.

Urine Chemokines as Biomarkers of Human Systemic Lupus Erythematosus Activity

The purpose of this study was to evaluate urine monocyte chemoattractant protein-1 (MCP-1) and IL-8 as biomarkers of SLE flare. Urine was collected every 2 mo from patients who were followed prospectively in the Ohio SLE Study. Renal and nonrenal flares were identified and MCP-1 and IL-8 were measured by specific ELISA in samples that were collected at flare. When available, MCP-1 and IL-8 were also measured in urine samples before and after flare. For comparison, MCP-1 and IL-8 were measured in the urine of healthy individuals and in renal and nonrenal SLE patients with stable disease activity (disease controls). Most patients were receiving maintenance immunosuppressive therapy before flare. At renal flare, mean urine MCP-1 (uMCP-1) was significantly greater than uMCP-1 at nonrenal flare and from healthy volunteers and renal disease controls. The level of uMCP-1 correlated with the increase in proteinuria at flare and was higher in patients with proliferative glomerulonephritis and in patients with impaired renal function. Urine MCP-1 was increased beginning 2 to 4 mo before flare. Patients who responded to therapy showed a slow decline in uMCP-1 over several months, whereas nonresponders had persistently high uMCP-1. In contrast, uIL-8 did not change with disease activity and was not elevated at renal or nonrenal flare compared with disease controls. In conclusion, uMCP-1 but not uIL-8 is a sensitive and specific biomarker of renal SLE flare and its severity, even in patients who receive significant immunosuppressive therapy. Persistently elevated uMCP-1 after treatment may indicate ongoing kidney injury that may adversely affect renal prognosis.